REFERENCES:

References for Earache

  1. Jackson EA and Geer K. Acute Otitis Externa: Rapid Evidence Review. American Family Physician. 2023;107(2):145-151.
  2. Hui C and Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Acute otitis externa. Paediatrics & Child Health, 2013;18(2):96-98.
  3. Sander R. Otitis External: A Practical Guide to Treatment and Prevention. American Family Physician. 2001;63(5):927 937.
  4. Osguthorpe JD, and Nielsen DR. Otitis externa: Review and clinical update. American Family Physician. 2006;74(9):1510-6.
  5. Artelac® Ear Drops instructions for use, 10.2023B_EN_IFU.

 

Proprietary name: Artelac® Ear Drops. Contains: 0,5 % solution of lidocaine hydrochloride in glycerol (anhydrous).
For full prescribing information, refer to the instructions for use.

For full prescribing information, refer to the instructions for use. Further information is available on request from Bausch + Lomb. © 2025 Bausch & Lomb Incorporated.
®/™ denote trademarks of Bausch & Lomb Incorporated. Distributed by: Soflens (Pty) Ltd.
Reg. No.: 1968/011787/07. 254 Hall Street, Centurion.
Tel: +27 010 025 2100.
www.bausch.co.za BL746/25

References for Dry Eye

  1. Stapleton F, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017 Jul;15(3):334-365.
  2. Wolffsohn JS, et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017 Jul;15(3):539-574.
  3. Labetoulle M, Bourcier T, et al. Classifying signs and symptoms of dry eye disease according to underlying mechanism via the Delphi method: the DIDACTIC study. Br J Ophthalmol 2019;103:1475–1480.
  4. Agarwal P, Craig JP, et al. Formulation Considerations for the Management of Dry Eye Disease.
    Pharmaceutics 2021;13:207.
  5. Chester T, Garg S, et al. How Can We Best Diagnose Severity Levels of Dry Eye Disease: Current Perspectives. Clinical Ophthalmology 2023:17 1587–1604.
  6. Tsubota K, Pflugfelder SC, et al. Defining Dry Eye from a Clinical Perspective. Int. J. Mol. Sci. 2020;21:9271.
  7. 2007 Report of the International Dry Eye Workshop (DEWS). Ocul Surf 2007;5(2):65-204.
  8. Rodriguez-Garcia A, Babayan-Sosa A, et al. A Practical Approach to Severity Classification and Treatment of Dry Eye Disease: A Proposal from the Mexican Dry Eye Disease Expert Panel. Clinical Ophthalmology 2022;16:1331–1355.
  9. Scheuer CA, et al. Retention of conditioning agent hyaluronan on hydrogel contact lenses.
    Contact Lens & Anterior Eye 2010,33(1S),2-6.
  10. Labetoulle M, Benitez-del-Castillo JM, et al. Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease. Int. J. Mol. Sci. 2022;23:2434.
  11. Artelac® Complete XP Eye Drops, instructions for use, I999EU-07;2024-08.
  12. Artelac® Advanced Lipids Eye Drops, instructions for use, I170EU-06, 2023-06.
  13. Artelac® Advanced Lipids Eye Lubricant Drops (UD), instructions for use, I168EU-03; 2023-06.
  14. Artelac® Advanced Lipids Eye Gel, instructions for use, I174EU-06; 2023-06.
  15. Artelac® Intense Rebalance Eye Drops, instructions for use, I781EU-08-Milan; 2024-09.
  16. Artelac® Splash Eye Drops, instructions for use, I931EU-06; 2023-06.
  17. Artelac® Moisture Eye Drops, instructions for use, I188EU-04; 2024-08.
  18. Data on File, Bausch & Lomb, South Africa
  19. Markoulli M, Ahmad S, et al. TFOS Lifestyle: Impact of nutrition on the ocular surface. The Ocular Surface 2023;29:226-271
  20. Nguyen L, Magno MS, et al. The relationship between sedentary behavior and dry eye disease.
    The Ocular Surface 2023;28:11-17.
  21. Navarro-Lopez S, Moya-Ramon M, et al. Effects of physical activity/exercise on tear film characteristics and dry eye associated symptoms: A literature review. Contact Lens and Anterior Eye 2023;46:101854
 

For full prescribing information, refer to the instructions for use. Further information is available on request from Bausch + Lomb. © 2025 Bausch & Lomb Incorporated.
®/™ denote trademarks of Bausch & Lomb Incorporated. Distributed by: Soflens (Pty) Ltd.
Reg. No.: 1968/011787/07. 254 Hall Street, Centurion.
Tel: +27 010 025 2100.
www.bausch.co.za BL746/25

References for Decision Tree

  1. Tsubota K, Pflugfelder SC, et al. Defining Dry Eye from a Clinical Perspective. Int. J. Mol. Sci. 2020;21:9271.
  2. Chester T, Garg S, et al. How Can We Best Diagnose Severity Levels of Dry Eye Disease: Current Perspectives. Clinical Ophthalmology 2023:17 1587–1604.
  3. Baab S, Le PH, et al. Allergic Conjunctivitis. StatPearls [Online] 26 Jan 2024. Available from https://
    www.ncbi.nlm.nih.gov/books/NBK448118/?report=printable. Accessed 2025/02/23.
  4. Artelac® Allergy Eye Drops, instructions for use, I228EU-04;2024-08.
  5. Artelac® Complete XP Eye Drops, instructions for use, I999EU-07;2024-08.
  6. Artelac® Advanced Lipids Eye Drops, instructions for use, I174EU-06;2023-06.
  7. Artelac® Intense Rebalance Eye Drops, instructions for use, I781EU-08-Milan;2024-09.
  8. Artelac® Splash Eye Drops, instructions for use, I931EU-06;2023-06.
  9. Artelac® Moisture Eye Drops, instructions for use, I188EU-04;2024-08.
  10. Jones L, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017 Jul;15(3):575-628
 

Proprietary name: Artelac® Complete XP Eye Drops. Contains: 0,24 % sodium hyaluronate, carbomer, glycerol, lipid component (medium chain triglycerides).
Proprietary name: Artelac® Advanced Lipids Eye Drops. Contains: 2 mg carbomer, medium chain triglycerides. Preservative: Cetrimide.
Proprietary name: Artelac® Advanced Lipids Eye Lubricant Drops (UD). Contains: 2 mg carbomer, medium chain triglycerides. Preservative free.
Proprietary name: Artelac® Advanced Lipids Eye Gel. Contains: 2 mg carbomer, medium chain triglycerides. Preservative: Cetrimide.
Proprietary name: Artelac® Intense Rebalance Eye Drops. Contains: 0,15 % hyaluronic acid (as sodium hyaluronate), 0,5 % polyethylene glycol 8000, potassium chloride, calcium chloride, magnesium chloride, sodium chloride, vitamin B12. Preservative: Oxyd® (a gentle preservative that converts to water, oxygen and salt at the surface of the eye).
Proprietary name: Artelac® Splash Eye Drops. Contains: 0,24 % hyaluronic acid (as sodium hyaluronate). Preservative free.
Proprietary name: Artelac® Moisture Eye Drops. Contains: 0,32 % hypromellose. Preservative: Cetrimide.

For full prescribing information, refer to the instructions for use. Further information is available on request from Bausch + Lomb. © 2025 Bausch & Lomb Incorporated.
®/™ denote trademarks of Bausch & Lomb Incorporated. Distributed by: Soflens (Pty) Ltd.
Reg. No.: 1968/011787/07. 254 Hall Street, Centurion.
Tel: +27 010 025 2100.
www.bausch.co.za BL746/25

References for Eye Allergies

  1. Sánchez-Hernández MC, et al. Consensus document on allergic conjunctivitis (DECA). J Investig Allergol Clin Immunol. 2015;25(2):94-106.
  2. Baab S, Le PH, et al. Allergic Conjunctivitis. StatPearls [Online] 26 Jan 2024. Available from https://www.ncbi.nlm.nih.gov/books/NBK448118/?report=printable. Accessed 2025/02/23.
  3. Chester T, Garg S, et al. How Can We Best Diagnose Severity Levels of Dry Eye Disease: Current Perspectives. Clinical Ophthalmology 2023:17 1587–1604.
  4. Artelac® Allergy Eye Drops, instructions for use, I228EU-02; 2023-06.
  5. Aragona P, et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002;86:181–184.

 

Proprietary name: Artelac® Allergy Eye Drops. Contains: 0,24 % hyaluronic acid (as sodium hyaluronate), 2 % Ectoin®. Preservative free.

For full prescribing information, refer to the instructions for use. Further information is available on request from Bausch + Lomb. © 2025 Bausch & Lomb Incorporated.
®/™ denote trademarks of Bausch & Lomb Incorporated. Distributed by: Soflens (Pty) Ltd.
Reg. No.: 1968/011787/07. 254 Hall Street, Centurion.
Tel: +27 010 025 2100.
www.bausch.co.za BL746/25